Among the many alternative strategies, epigenetic therapy is regarded as a promising method [1], and a histone deacetylase (HDAC) inhibitor [2] or DNA methyltransferase inhibitor [3] were shown to be promising NSCLC treatments, especially when combined [1]. This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.